On Tuesday, Laidlaw initiated coverage on BiomX (NYSE:PHGE), a mid-clinical stage biotechnology company, with a Buy rating and set a price target at $2.50. BiomX is currently developing phage-based anti-infective therapies. The company has two significant Phase II studies in progress, one for cystic fibrosis (CF) and the other for diabetic foot osteomyelitis (DFO). The top-line results for these studies are anticipated in the third quarter of 2025 and the first quarter of 2025, respectively.
According to Laidlaw's analysis, BiomX's shares are currently undervalued when considering the company's promising pipeline of phage-based therapeutics. The firm suggests that BiomX's stock presents an opportunity for long-term investors who are comfortable with a higher level of risk.
The price target of $2.50 set by Laidlaw for BiomX shares is based on a combination of forward price-to-earnings (P/E) and net present value (NPV)-driven sum-of-the-parts analyses. This valuation reflects the firm's positive outlook on the potential of BiomX's therapeutic pipeline and its future performance.
InvestingPro Insights
As BiomX (NYSE:PHGE) navigates through its mid-clinical stage developments, investors may find value in the latest insights from InvestingPro. With a market capitalization of $18.77 million, BiomX's financial position holds a unique combination of strengths and challenges. An InvestingPro Tip highlights that the company holds more cash than debt on its balance sheet, suggesting a level of financial stability that might reassure investors. Additionally, the strong return over the last three months, with a 58.07% price total return, indicates a positive short-term momentum that could catch the attention of investors seeking growth.
Conversely, it's important to note that BiomX has been quickly burning through cash, and analysts do not anticipate the company will be profitable this year. Moreover, the company's P/E ratio stands at -0.55, reflecting market skepticism about future earnings. This aligns with the InvestingPro Data, which shows a notable Return on Assets at -60.38% for the last twelve months as of Q1 2024, underscoring the company's current challenges in generating profitability from its assets.
For investors interested in deeper analysis, InvestingPro offers additional tips for BiomX, providing a comprehensive look at the company's financial health and market potential. Take advantage of this expert analysis with a special offer: use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Discover more InvestingPro Tips and stay ahead in making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.